Italia markets closed
FTSE MIB
34.657,35 +318,03 (+0,93%) Dow Jones
39.512,84 +125,08 (+0,32%) Nasdaq
16.340,87 -5,40 (-0,03%) Nikkei 225
38.229,11 +155,13 (+0,41%) Petrolio
78,20 -1,06 (-1,34%) Bitcoin EUR
56.587,12 -1.761,11 (-3,02%)
BMY Nov 2025 50.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 10:54AM EDT
| Chiusura precedente | 3,3000 |
| Aperto | 3,3000 |
| Denaro | 3,7500 |
| Lettera | 3,9500 |
| Prezzo d'esercizio | 50,00 |
| Scadenza | 2025-11-21 |
| Min-Max giorno | 3,3000 - 3,3000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 255 |
GlobeNewswireArbutus Appoints Two New Executives
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Chri
© 2024 Yahoo. Tutti i diritti riservati.